Showing results (561-570 of 635) with videos related to

Sort By:
Pageof 64
JACC. Heart Failure|June 9, 2023
Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy StatusAlexander Peikert, Parag Goyal, Muthiah Vaduganathan, et al.
European Journal of Heart Failure|April 11, 2026
Effects of Finerenone Across a Range of Heart Failure Duration: A Prespecified Analysis of the FINEARTS-HF TrialYasuhiro Hamatani, John W Ostrominski, Henri Lu, et al.
Circulation|April 9, 2021
Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HFPardeep S Jhund, Piotr Ponikowski, Kieran F Docherty, et al.
European Journal of Heart Failure|May 3, 2024
Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fractionMingming Yang, Toru Kondo, Atefeh Talebi, et al.
JCSM Communications|January 22, 2026
Automated Segmentation of Forearm Muscles: Clinical Associations With Hand Function, Muscle Volume and Intramuscular FatJoel Fundaun, Valeria Oliva, Sandrine Bédard, et al.
Circulation. Heart Failure|October 27, 2023
Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVERToru Kondo, Jawad H Butt, James P Curtain, et al.
JAMA Cardiology|March 28, 2026
Biomarker, Functional Status, and Quality-of-Life Trajectories Before Modes of Death in Heart Failure: Post Hoc Analysis of the FINEARTS-HF Randomized Clinical TrialHenri Lu, Annamaria Kosztin, Brian L Claggett, et al.
JAMA Cardiology|November 3, 2022
Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical TrialFinnian R Mc Causland, Brian L Claggett, Muthiah Vaduganathan, et al.
Circulation|June 6, 2024
Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HFPooja Dewan, Li Shen, João Pedro Ferreira, et al.
European Journal of Heart Failure|November 7, 2022
Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartanMingming Yang, Jawad H Butt, Toru Kondo, et al.
Pageof 64